Clinical Trial

Evaluation of the Efficacy of HIFU Treatment on Rectal Endometriosis Symptoms.

Study acronym: ENDO-HIFU-R2
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Rectal endometriosis (RE) induces lesions associated with painful symptoms that can alter quality of life. High Intensity Focused Ultrasound (HIFU) is a non-invasive ablative procedure using a high-intensity ultrasound probe to induce tissue devitalization using acoustic cavitation and thermal ablation. Focal One® is a transrectal HIFU device, which is validated to treat prostatic cancer. In this comparative, randomized, double blind study , the primary objective is to evaluate the efficacy of the HIFU treatment of rectal endometriosis with Focal One® HIFU device on the Acute Pelvic Pain 3 months after HIFU treatment, in comparison to a Sham group.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-02-23; most recent amendment 2025-06-02.
Status change: Recruiting → Active, Not Recruiting 2024-04-18
Trial Details
NCT Number NCT05755958
Lead Sponsor EDAP TMS S.A.
Conditions Endometriosis
Enrollment 60 participants
Start Date 2023-02-03
Primary Completion 2024-01-23 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-05